Advances in clinical chemistry最新文献_第5页

Cortisol in metabolic syndrome. 代谢综合征中的皮质醇

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-06-24 DOI: 10.1016/bs.acc.2024.06.008

Eglė Mazgelytė, Dovilė Karčiauskaitė

引用次数: 0

Fibrinogen: Structure, abnormalities and laboratory assays. 纤维蛋白原：结构、异常和实验室检测。

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-30 DOI: 10.1016/bs.acc.2024.03.004

Berrak Güven, Murat Can

引用次数: 0

Blood-brain barrier biomarkers. 血脑屏障生物标志物

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-22 DOI: 10.1016/bs.acc.2024.04.004

Juan F Zapata-Acevedo, Alejandra Mantilla-Galindo, Karina Vargas-Sánchez, Rodrigo E González-Reyes

{"title":"Blood-brain barrier biomarkers.","authors":"Juan F Zapata-Acevedo, Alejandra Mantilla-Galindo, Karina Vargas-Sánchez, Rodrigo E González-Reyes","doi":"10.1016/bs.acc.2024.04.004","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.04.004","url":null,"abstract":"The blood-brain barrier (BBB) is a dynamic interface that regulates the exchange of molecules and cells between the brain parenchyma and the peripheral blood. The BBB is mainly composed of endothelial cells, astrocytes and pericytes. The integrity of this structure is essential for maintaining brain and spinal cord homeostasis and protection from injury or disease. However, in various neurological disorders, such as traumatic brain injury, Alzheimer's disease, and multiple sclerosis, the BBB can become compromised thus allowing passage of molecules and cells in and out of the central nervous system parenchyma. These agents, however, can serve as biomarkers of BBB permeability and neuronal damage, and provide valuable information for diagnosis, prognosis and treatment. Herein, we provide an overview of the BBB and changes due to aging, and summarize current knowledge on biomarkers of BBB disruption and neurodegeneration, including permeability, cellular, molecular and imaging biomarkers. We also discuss the challenges and opportunities for developing a biomarker toolkit that can reliably assess the BBB in physiologic and pathophysiologic states.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"121 ","pages":"1-88"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital biomarkers in Parkinson's disease. 帕金森病的数字生物标记。

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-06-22 DOI: 10.1016/bs.acc.2024.06.005

Anastasia Bougea

引用次数: 0

Glycosaminoglycans in mucopolysaccharidoses and other disorders. 粘多糖病和其他疾病中的糖胺聚糖。

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-07-23 DOI: 10.1016/bs.acc.2024.06.011

Shaukat A Khan, Fnu Nidhi, Andrés Felipe Leal, Betul Celik, Angelica María Herreño-Pachón, Sampurna Saikia, Eliana Benincore-Flórez, Yasuhiko Ago, Shunji Tomatsu

{"title":"Glycosaminoglycans in mucopolysaccharidoses and other disorders.","authors":"Shaukat A Khan, Fnu Nidhi, Andrés Felipe Leal, Betul Celik, Angelica María Herreño-Pachón, Sampurna Saikia, Eliana Benincore-Flórez, Yasuhiko Ago, Shunji Tomatsu","doi":"10.1016/bs.acc.2024.06.011","DOIUrl":"10.1016/bs.acc.2024.06.011","url":null,"abstract":"Glycosaminoglycans (GAGs) are sulfated polysaccharides comprising repeating disaccharides, uronic acid (or galactose) and hexosamines, including chondroitin sulfate, dermatan sulfate, heparan sulfate, and keratan sulfate. Hyaluronan is an exception in the GAG family because it is a non-sulfated polysaccharide. Lysosomal enzymes are crucial for the stepwise degradation of GAGs to provide a normal function of tissues and extracellular matrix (ECM). The deficiency of one or more lysosomal enzyme(s) results in the accumulation of undegraded GAGs, causing cell, tissue, and organ dysfunction. Accumulation of GAGs in various tissues and ECM results in secretion into the circulation and then excretion in urine. GAGs are biomarkers of certain metabolic disorders, such as mucopolysaccharidoses (MPS) and mucolipidoses. GAGs are also elevated in patients with various conditions such as respiratory and renal disorders, fatty acid metabolism disorders, viral infections, vomiting disorders, liver disorders, epilepsy, hypoglycemia, myopathy, developmental disorders, hyperCKemia, heart disease, acidosis, and encephalopathy. MPS are a group of inherited metabolic diseases caused by the deficiency of enzymes required to degrade GAGs in the lysosome. Eight types of MPS are categorized based on lack or defect in one of twelve specific lysosomal enzymes and are described as MPS I through MPS X (excluding MPS V and VIII). Clinical features vary with the type of MPS and clinical severity of the disease. This chapter addresses the historical overview, synthesis, degradation, distribution, biological role, and method for measurement of GAGs.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"122 ","pages":"1-52"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sputum proteomics in lung disorders. 肺部疾病中的痰蛋白质组学。

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-06-18 DOI: 10.1016/bs.acc.2024.06.002

Paolo Iadarola, Maura D'Amato, Maria Antonietta Grignano, Simona Viglio

{"title":"Sputum proteomics in lung disorders.","authors":"Paolo Iadarola, Maura D'Amato, Maria Antonietta Grignano, Simona Viglio","doi":"10.1016/bs.acc.2024.06.002","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.06.002","url":null,"abstract":"Lung diseases affect pulmonary and respiratory function and are caused by bacterial viral and fungal infection as well as environmental factors. Unfortunately, symptom overlap between various pulmonary diseases often prevents clear differentiation and uncertain diagnosis. Accordingly, identification of specific markers of inflammatory activity in early disease stage could potential unveil the intrinsic molecular mechanisms of the underlying pathology. Proteomic studies aimed at understanding the genetic/environmental contributions to the development and progression of lung diseases represent a promising approach for diagnosis and treatment. The fluid phase of sputum represents a rich protein source and is frequently used in these studies. This chapter addresses causes of lung disorders, sputum composition, collection and processing as well as the clinical significance and challenges associated with the presence of interfering factors. Basics of proteomics and mass spectrometry are also described, together with the analytical approaches to investigate the sputum proteome. Finally, we explore the application of sputum proteomics in severe lung disorders including COVID-19 infection, chronic obstructive pulmonary disease, asthma, cystic fibrosis, lung cancer and tuberculosis.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"122 ","pages":"171-208"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Defining allowable total error limits in the clinical laboratory. 定义临床实验室允许的总误差限值。

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2023-12-20 DOI: 10.1016/bs.acc.2023.11.006

Jill Palmer, Kornelia Galior

引用次数: 0

Autoantibody evaluation in idiopathic inflammatory myopathies. 特发性炎症性肌病的自身抗体评估。

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-16 DOI: 10.1016/bs.acc.2024.04.001

Anne E Tebo

{"title":"Autoantibody evaluation in idiopathic inflammatory myopathies.","authors":"Anne E Tebo","doi":"10.1016/bs.acc.2024.04.001","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.04.001","url":null,"abstract":"Idiopathic inflammatory myopathies (IIM), generally referred to as myositis is a heterogeneous group of diseases characterized by muscle inflammation and/or skin involvement, diverse extramuscular manifestations with variable risk for malignancy and response to treatment. Contemporary clinico-serologic categorization identifies 5 main clinical groups which can be further stratified based on age, specific clinical manifestations and/or risk for cancer. The serological biomarkers for this classification are generally known as myositis-specific (MSAs) and myositis-associated antibodies. Based on the use of these antibodies, IIM patients are classified into anti-synthetase syndrome, dermatomyositis, immune-mediated necrotizing myopathy, inclusion body myositis, and overlap myositis. The current classification criteria for IIM requires clinical findings, laboratory measurements, and histological findings of the muscles. However, the use MSAs and myositis-associated autoantibodies as an adjunct for disease evaluation is thought to provide a cost-effective personalized approach that may not only guide diagnosis but aid in stratification and/or prognosis of patients. This review provides a comprehensive overview of contemporary autoantibodies that are specific or associated myositis. In addition, it highlights possible pathways for the detection and interpretation of these antibodies with limitations for routine clinical use.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"120 ","pages":"45-67"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Myocardial fibrosis in right heart dysfunction. 右心功能不全的心肌纤维化

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-02-22 DOI: 10.1016/bs.acc.2024.02.005

Lucia Agoston-Coldea, Andra Negru

引用次数: 0

Advances in periodontal biomarkers. 牙周生物标志物的研究进展。

Advances in clinical chemistry Pub Date : 2024-01-01 Epub Date: 2024-04-18 DOI: 10.1016/bs.acc.2024.03.003

Ulvi Kahraman Gürsoy, Meltem Özdemir Kabalak, Mervi Gürsoy

{"title":"Advances in periodontal biomarkers.","authors":"Ulvi Kahraman Gürsoy, Meltem Özdemir Kabalak, Mervi Gürsoy","doi":"10.1016/bs.acc.2024.03.003","DOIUrl":"https://doi.org/10.1016/bs.acc.2024.03.003","url":null,"abstract":"Due to technologic advancements, periodontology has witnessed a boost in biomarker research over the past three decades. Indeed, with the aid of omics, our understanding of the healthy periodontium, pathogenesis of periodontal diseases, and healing after periodontal treatment has improved significantly. Yet, the traditional methods, periodontal probing and radiographies, remain the most common methods to diagnose periodontal disease and monitor treatment. Although these approaches can produce reliable diagnostic outcomes, they generally detect disease only after significant tissue degradation thus making treatment outcome highly uncertain. Accordingly, laboratories worldwide have collaborated with clinicians to design accurate, rapid and cost-effective biomarkers for periodontal disease diagnosis. Despite these efforts, biomarkers that can be widely used in early disease diagnosis and for treatment outcome prediction are far from daily use. The aim of this chapter is to give a general overview on periodontal health and diseases, and review recent advancements in periodontal biomarker research. A second aim will discuss the strengths and limitations of translating periodontal biomarker research to clinical practice. Genetic biomarkers of periodontitis are not discussed as the available confirmatory data is scarce.","PeriodicalId":101297,"journal":{"name":"Advances in clinical chemistry","volume":"120 ","pages":"145-168"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0